{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:24Z","timestamp":1787113644920,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116893","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:49:46Z","timestamp":1781851786000},"page":"116893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3280-8464","authenticated-orcid":false,"given":"Linde","family":"van den Hoek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-291X","authenticated-orcid":false,"given":"Mark","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2026.116893_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116893_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116893_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0197-2456(01)00113-1","article-title":"Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14","volume":"22","author":"Moy","year":"2001","journal-title":"Control Clin Trials"},{"issue":"8","key":"10.1016\/j.ejca.2026.116893_bib4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116893_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"24","key":"10.1016\/j.ejca.2026.116893_bib6","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2026.116893_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116893_bib8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","article-title":"Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study","volume":"28","author":"Meijer","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116893_bib9","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","article-title":"Efficacy and Safety of the Melphalan\/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","volume":"31","author":"Zager","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116893_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1017\/rsm.2025.10024","article-title":"Simple imputation method for meta-analysis of survival rates when precision information is missing","volume":"16","author":"Maruo","year":"2025","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ejca.2026.116893_bib11","unstructured":"Higgins J., Thomas J., Chandler J., Cumpston M., Li T., Page M. Cochrane Handbook for Systematic Reviews of Interventions version 6.5: Cochrane; 2024."},{"issue":"23","key":"10.1016\/j.ejca.2026.116893_bib12","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.3390\/cancers17233834","article-title":"Survival outcome after percutaneous hepatic perfusion with high-dose melphalan for liver-dominant metastatic uveal melanoma: a 10-year single-center experience","volume":"17","author":"Reiner","year":"2025","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.ejca.2026.116893_bib13","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1245\/s10434-024-16039-5","article-title":"Hepatic and overall progression-free survival after percutaneous hepatic perfusion (PHP) as first-line or second-line therapy for metastatic uveal melanoma","volume":"31","author":"Ghali","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116893_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00270-022-03225-9","article-title":"Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis","volume":"45","author":"Tong","year":"2022","journal-title":"Cardiovasc Interv Radiol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116893_bib15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1055\/a-1348-1932","article-title":"Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma","volume":"193","author":"Dewald","year":"2021","journal-title":"RoFo Fortschr auf dem Geb der Rontgenstrahlen und der Bildgeb Verfahr"},{"issue":"11","key":"10.1016\/j.ejca.2026.116893_bib16","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s00432-020-03289-5","article-title":"Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma","volume":"146","author":"Schonfeld","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116893_bib17","article-title":"Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan - long-term overall survival negatively correlates with tumor burden","volume":"2020","author":"Bruning","year":"2020","journal-title":"Radiol Res Pract"},{"key":"10.1016\/j.ejca.2026.116893_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience","volume":"19","author":"Artzner","year":"2019","journal-title":"CANCER IMAGING"},{"issue":"20","key":"10.1016\/j.ejca.2026.116893_bib19","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.3390\/cancers15204942","article-title":"Selective internal radiotherapy (SIRT) and chemosaturation percutaneous hepatic perfusion (CS-PHP) for metastasized uveal melanoma: a retrospective comparative study","volume":"15","author":"Kolb","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2026.116893_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010118","article-title":"Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: The German Experience","volume":"14","author":"Dewald","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ejca.2026.116893_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/02841851211019808","article-title":"Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma","volume":"63","author":"Estler","year":"2022","journal-title":"Acta Radiol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116893_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease","volume":"117","author":"Karydis","year":"2018","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116893_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CMR.0000000000000806","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma","volume":"32","author":"Modi","year":"2022","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.ejca.2026.116893_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1470-2045(25)00720-X","article-title":"Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial","volume":"27","author":"van den Hoek","year":"2026","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116893_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study","volume":"40","author":"Vogl","year":"2017","journal-title":"Cardiovasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116893_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/SLA.0000000000006255","article-title":"Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM","volume":"282","author":"Olofsson Bagge","year":"2025","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.ejca.2026.116893_bib27","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1245\/s10434-025-17231-x","article-title":"An Open-label, Randomized Study of Melphalan\/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma","volume":"32","author":"Zager","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.116893_bib28","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1245\/s10434-025-18092-0","article-title":"Response to Letter to the Editor Regarding: An Open-Label, Randomized Study of Melphalan\/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma","volume":"32","author":"Zager","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116893_bib29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116893_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00432-025-06291-x","article-title":"Subgroup analyses of the phase 3 FOCUS study of melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma","volume":"152","author":"Zager","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116893_bib31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","article-title":"Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan","volume":"40","author":"de Leede","year":"2017","journal-title":"Cardiovasc Interv Radiol"},{"issue":"24","key":"10.1016\/j.ejca.2026.116893_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246390","article-title":"Combination of immune checkpoint inhibitors and liver-specific therapies in liver-metastatic uveal melanoma: can we thus overcome its high resistance?","volume":"13","author":"Blomen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ejca.2026.116893_bib33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11684-023-0993-y","article-title":"Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial","volume":"17","author":"Koch","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.ejca.2026.116893_bib34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fonc.2018.00570","article-title":"Isolated limb perfusion with melphalan triggers immune activation in melanoma patients","volume":"8","author":"Johansson","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116893_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1854519","article-title":"Presence of tumor-infiltrating CD8(+) T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis","volume":"9","author":"Johansson","year":"2020","journal-title":"Oncoimmunology"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600674X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600674X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:14:24Z","timestamp":1787112864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600674X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S095980492600674X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116893","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116893"}}